Literature DB >> 32923851

Prioritization of Therapy Options for a Patient With High Tumor Mutation Burden and Microsatellite Instability but No Clinical Benefit From Immunotherapy.

Ryan S Nelson1, Rutika J Mehta1, Howard L McLeod1, Christine M Walko1.   

Abstract

Entities:  

Year:  2019        PMID： 32923851      PMCID： PMC7446362          DOI： 10.1200/PO.19.00197

Source DB:  PubMed          Journal:  JCO Precis Oncol        ISSN： 2473-4284


× No keyword cloud information.
  14 in total

1.  Therapeutic Response of Metastatic Colorectal Cancer Harboring a KRAS Missense Mutation After Combination Chemotherapy With the EGFR Inhibitor Panitumumab.

Authors:  Emil Lou; Donna D'Souza; Andrew C Nelson
Journal:  J Natl Compr Canc Netw       Date:  2017-04       Impact factor: 11.908

2.  Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study.

Authors:  Michael J Overman; Ray McDermott; Joseph L Leach; Sara Lonardi; Heinz-Josef Lenz; Michael A Morse; Jayesh Desai; Andrew Hill; Michael Axelson; Rebecca A Moss; Monica V Goldberg; Z Alexander Cao; Jean-Marie Ledeine; Gregory A Maglinte; Scott Kopetz; Thierry André
Journal:  Lancet Oncol       Date:  2017-07-19       Impact factor: 41.316

Review 3.  The ATM protein kinase: regulating the cellular response to genotoxic stress, and more.

Authors:  Yosef Shiloh; Yael Ziv
Journal:  Nat Rev Mol Cell Biol       Date:  2013-03-13       Impact factor: 94.444

4.  DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.

Authors:  Joaquin Mateo; Suzanne Carreira; Shahneen Sandhu; Susana Miranda; Helen Mossop; Raquel Perez-Lopez; Daniel Nava Rodrigues; Dan Robinson; Aurelius Omlin; Nina Tunariu; Gunther Boysen; Nuria Porta; Penny Flohr; Alexa Gillman; Ines Figueiredo; Claire Paulding; George Seed; Suneil Jain; Christy Ralph; Andrew Protheroe; Syed Hussain; Robert Jones; Tony Elliott; Ursula McGovern; Diletta Bianchini; Jane Goodall; Zafeiris Zafeiriou; Chris T Williamson; Roberta Ferraldeschi; Ruth Riisnaes; Bernardette Ebbs; Gemma Fowler; Desamparados Roda; Wei Yuan; Yi-Mi Wu; Xuhong Cao; Rachel Brough; Helen Pemberton; Roger A'Hern; Amanda Swain; Lakshmi P Kunju; Rosalind Eeles; Gerhardt Attard; Christopher J Lord; Alan Ashworth; Mark A Rubin; Karen E Knudsen; Felix Y Feng; Arul M Chinnaiyan; Emma Hall; Johann S de Bono
Journal:  N Engl J Med       Date:  2015-10-29       Impact factor: 91.245

5.  ARID1A Deficiency Impairs the DNA Damage Checkpoint and Sensitizes Cells to PARP Inhibitors.

Authors:  Jianfeng Shen; Yang Peng; Leizhen Wei; Wei Zhang; Lin Yang; Li Lan; Prabodh Kapoor; Zhenlin Ju; Qianxing Mo; Ie-Ming Shih; Ivan P Uray; Xiangwei Wu; Powel H Brown; Xuetong Shen; Gordon B Mills; Guang Peng
Journal:  Cancer Discov       Date:  2015-06-11       Impact factor: 39.397

6.  Systematic Functional Interrogation of Rare Cancer Variants Identifies Oncogenic Alleles.

Authors:  Eejung Kim; Nina Ilic; Yashaswi Shrestha; Lihua Zou; Atanas Kamburov; Cong Zhu; Xiaoping Yang; Rakela Lubonja; Nancy Tran; Cindy Nguyen; Michael S Lawrence; Federica Piccioni; Mukta Bagul; John G Doench; Candace R Chouinard; Xiaoyun Wu; Larson Hogstrom; Ted Natoli; Pablo Tamayo; Heiko Horn; Steven M Corsello; Kasper Lage; David E Root; Aravind Subramanian; Todd R Golub; Gad Getz; Jesse S Boehm; William C Hahn
Journal:  Cancer Discov       Date:  2016-05-04       Impact factor: 39.397

Review 7.  PARP Inhibitors: Extending Benefit Beyond BRCA-Mutant Cancers.

Authors:  Patrick G Pilié; Carl M Gay; Lauren A Byers; Mark J O'Connor; Timothy A Yap
Journal:  Clin Cancer Res       Date:  2019-02-13       Impact factor: 12.531

8.  Efficiency of olaparib in colorectal cancer patients with an alteration of the homologous repair protein.

Authors:  Francois Ghiringhelli; Corentin Richard; Sandy Chevrier; Frédérique Végran; Romain Boidot
Journal:  World J Gastroenterol       Date:  2016-12-28       Impact factor: 5.742

9.  SMAD4 and NF1 mutations as potential biomarkers for poor prognosis to cetuximab-based therapy in Chinese metastatic colorectal cancer patients.

Authors:  Zhu Mei; Yang W Shao; Peinan Lin; Xiaomin Cai; Biao Wang; Yan Ding; Xiangyuan Ma; Xue Wu; Yewei Xia; Dongqin Zhu; Yongqian Shu; Zan Fu; Yanhong Gu
Journal:  BMC Cancer       Date:  2018-04-27       Impact factor: 4.430

10.  ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A.

Authors:  Chris T Williamson; Rowan Miller; Helen N Pemberton; Samuel E Jones; James Campbell; Asha Konde; Nicholas Badham; Rumana Rafiq; Rachel Brough; Aditi Gulati; Colm J Ryan; Jeff Francis; Peter B Vermulen; Andrew R Reynolds; Philip M Reaper; John R Pollard; Alan Ashworth; Christopher J Lord
Journal:  Nat Commun       Date:  2016-12-13       Impact factor: 14.919
View more
  1 in total

1.  ARID1A genomic alterations driving microsatellite instability through somatic MLH1 methylation with response to immunotherapy in metastatic lung adenocarcinoma: a case report.

Authors:  Mercedes Durán; Iris Faull; Enrique Lastra; Jean-Francois Laes; Ana Belén Rodrigo; Ricardo Sánchez-Escribano
Journal:  J Med Case Rep       Date:  2021-02-19
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.